Dr Ana Alfirevic MD, PhD, Professor of Pharmacology and Personalised Medicine at Institute of Translational Medicine, University of Liverpool
Dr Ana Alfirevic research has been focused on molecular pharmacology and pharmacogenetics. She has been working on discovery and implementation of genetic factors predisposing to immune-mediated adverse drug reactions (ADRs). In cardiovascular pharmacology, her research aims at investigating genetic factors predisposing to statin-induced myopathy by utilizing next generation sequencing strategy.
She is also involved in public health research via the National Institute of Health Research (NIHR) Collaboration for Leadership in Applied Health Research and Care North West Coast (CLAHRC NWC), where she is a co-lead for the Delivering Personalised Health and Care theme. The overarching aim of the programme is to tackle health inequalities. Within CLAHRC, the project on genotype guided dosing of warfarin is being implemented into clinical practice.